Lineage Cell Therapeutics(LCTX) - 2023 Q4 - Annual Results

LINEAGE CELL THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE o Continued execution under our collaboration with Roche and Genentech across multiple functional areas, including support for the ongoing Phase 2a clinical study in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). o Long-term follow-up of patients from the Phase 1/2a clinical study of OpRegen: ▪ Positive clinical data presented at 2023 Eyecelerator, 23 ...